
Ondine Biomedical has reported a 40% relative reduction in 30-day surgical-site infections (SSIs) in a 5,188-patient phase 3 trial of …
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care

